logo-loader
ValiRx PLC

ValiRX raises funds to meet immediate working capital needs and develop drugs

ValiRX expects to pay European High Growth Opportunities Securitisation Fund up to £150,000 to terminate a subscription agreement.

biotech
ValiRX will also receive £550K from a tax credit and the sale of an unlisted security

ValiRx Plc (LON:VAL) has raised £300,000 through a share placing to address its immediate working capital needs and to develop key drugs.

The biotechnology company issued 150mln new ordinary shares at a price of 0.2p per share.

READ: ValiRx monitors working capital position amid talks to end subscription agreement with investor

The net proceeds of the placing will be used for working capital and to fund the Phase I/II clinical trial of prostate cancer treatment, VAL201, and to develop ValiRx's pre-clinical treatments, including VAL301 for endometriosis and VAL101 for killing off cancer cells.

ValiRX also expects to shortly receive £150,000 in proceeds from the sale of an unlisted security along with a research and development tax credit of £400,000 from the HMRC in July.

The company has been monitoring its working capital position as talks to terminate a subscription agreement with European High Growth Opportunities Securitisation Fund continue.

In late April, European High Growth agreed to subscribe for a total of 213mln shares in ValiRX at a price of 0.6p each, raising gross proceeds of £1.28mln.

The money was to be drawn down in three equal tranches of £426,000, which would have helped fund the Phase II trial of ValiRx's prostate cancer drug, VAL201, through to completion.

However, last month ValiRX said it was in advanced discussions to terminate the agreement following a delay to the issue of Tranche 2 shares.

On Thursday, ValiRX said it had still not reached a definitive agreement with European High Growth but expects to pay the investor up to £150,000 to end the deal.

Quick facts: ValiRx PLC

Price: 0.1301 GBX

Market: AIM
Market Cap: £1.74 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Commercial discussions for ValiRx's lead cancer drug progressing 'rapidly'

George Morris, chief operations officer of ValiRx Plc (LON:VAL), tells Proactive's Andrew Scott commercial discussions to take their lead drug VAL 401 into a Phase III trial are progressing rapidly. He says by nature they're detailed and complex but he hopes they'll be completed shortly...

on 6/9/18

RNS

Holding(s) in Company

1 week, 2 days ago

Appointment of Joint Broker

1 week, 2 days ago

Holding(s) in Company

1 week, 4 days ago

Half-year Report

on 26/9/19

Company Update

on 24/9/19

2 min read